James Hemphill
About James Hemphill
James Hemphill is a Principal Scientist specializing in cell therapy at SalioGen Therapeutics, with a background in chemistry and extensive experience in the field of cell engineering. He has held positions at various organizations, including Kytopen and Flagship Pioneering, and earned his Ph.D. from the University of Pittsburgh.
Current Role at SalioGen Therapeutics
James Hemphill serves as Principal Scientist in Cell Therapy at SalioGen Therapeutics, a position he has held since 2022. His work focuses on advancing cell therapy technologies, contributing to the development of innovative treatments. SalioGen Therapeutics is located in Woburn, Massachusetts, where Hemphill applies his expertise in cell engineering to support the company's mission.
Previous Experience at Flagship Pioneering
Prior to his current role, Hemphill worked as a Senior Scientist in Cell Engineering at Flagship Pioneering from 2021 to 2022. During his eight-month tenure in Cambridge, Massachusetts, he engaged in projects that aimed to enhance cell engineering methodologies, furthering the field of cellular therapies.
Professional Background at Kytopen
James Hemphill was employed as Principal Scientist at Kytopen from 2018 to 2021. His three years at the company in Cambridge, Massachusetts, involved leading research initiatives in cell engineering, contributing to the development of novel technologies for cell manipulation and therapy.
Educational Background and Doctorate Studies
Hemphill earned his Doctor of Philosophy (Ph.D.) in Chemistry from the University of Pittsburgh, where he studied from 2013 to 2015. His academic journey began with a Bachelor of Science in Molecular Genetics from the University of Vermont, completed in 2007. He also attended North Carolina State University, where he pursued a Ph.D. in Chemistry before transferring to the University of Pittsburgh.
Research Experience at Archemix
James Hemphill worked as a Research Associate in Aptamer Discovery at Archemix from 2007 to 2010. His role involved conducting research in Cambridge, Massachusetts, focusing on the discovery and development of aptamers, which are short, single-stranded RNA or DNA molecules that can bind to specific targets.